Selected Quarterly Financial Information (Unaudited)

12 Months Ended

Dec. 31, 2017

Quarterly Financial Information Disclosure [Abstract]

Selected Quarterly Financial Information (Unaudited)

16. Selected Quarterly Financial Information (UNAUDITED, in thousands, except per share data)

BioTime has derived this data from the unaudited consolidated interim financial statements that, in BioTime’ s opinion, have been prepared on substantially the same basis as the audited consolidated financial statements contained herein and include all normal recurring adjustments necessary for a fair presentation of the financial information for the periods presented. These unaudited consolidated quarterly results should be read in conjunction with the consolidated financial statements and notes thereto included herein. The consolidated operating results in any quarter are not necessarily indicative of the consolidated results that may be expected for any future period.

Year Ended December 31, 2017	First Quarter		Second Quarter		Third Quarter		Fourth Quarter
Revenues, net	$	333	$	376	$	1,636	$	945
Operating expenses		11,595		10,694		11,149		10,508
Loss from operations		(11,262)		(8,564)		(9,513)		(9,563)
Net income (loss) attributable to BioTime		49,288		(11,651)		14,321		(71,934)
Basic net income (loss) per share	$	0.46	$	(0.11)	$	0.12	$	(0.58)
Year Ended December 31, 2016
Revenues, net	$	1,848	$	1,171	$	1,441	$	1,103
Operating expenses		25,606		15,574		10,996		12,356
Loss from operations		(23,758)		(14,403)		(9,555)		(11,253)
Net income (loss) attributable to BioTime		(17,112)		24,549		31,199		(4,945)
Basic net income (loss) per share	$	(0.19)	$	0.26	$	0.30	$	(0.05)

Quarterly and year-to-date computations of net income (loss) per share amounts are calculated using the respective period weighted average shares outstanding. Therefore, the sum of the per share amounts for the quarters may not agree with the per share amounts for the year.